Case Study Marketing Authorization Transfer
In this client success story, a mid-sized biopharma company acquired an existing product portfolio from another company. There were eight products initially, spanning over 30 countries, focused on cardiovascular and transdermal patches. By using a flexible resourcing model we enabled cost and resource efficiencies in this marketing authorization transfer project.
Related Insights
CTB Blog
Engage early, design once: turning early-phase trials into a program strategy
Sep 10, 2026
CTB Blog
Five Practical Strategies for Accelerating Early Phase Studies
Aug 19, 2026
Article
Reading current FDA and NMPA trends: What oncology tells us about the changing regulatory landscape
Jul 21, 2026
CTB Blog
Modernizing data operations to enable today's Phase 1 trials
Jul 1, 2026
Blog
A Deep Dive into the Genetic Therapies Bootcamp at the ACMG 2026 Annual Meeting
Jun 23, 2026
Video
Bench-to-bedside: Transforming scientific breakthroughs into clinical success
Apr 3, 2026
CTB Blog
Even when capital flows freely, biotechs benefit from efficiency
Mar 24, 2026
CTB Blog
5 ways to secure biotech funding in 2026
Mar 19, 2026
Article
Case study: Protecting Phase 2 obesity retention and study timelines
Mar 18, 2026
CTB Webinar
Extend your funding runway: How to maintain capital efficiency in an improving market
Mar 10, 2026
Blog
Bolster your investor narrative with RWE
Jan 26, 2026
Blog
Investor-ready evidence planning: Why a robust strategy matters to funders
Dec 8, 2025
Related Insights
CTB Blog
Engage early, design once: turning early-phase trials into a program strategy
Sep 10, 2026
CTB Blog
Five Practical Strategies for Accelerating Early Phase Studies
Aug 19, 2026
Article
Reading current FDA and NMPA trends: What oncology tells us about the changing regulatory landscape
Jul 21, 2026
CTB Blog
Modernizing data operations to enable today's Phase 1 trials
Jul 1, 2026
Blog
A Deep Dive into the Genetic Therapies Bootcamp at the ACMG 2026 Annual Meeting
Jun 23, 2026
Video
Bench-to-bedside: Transforming scientific breakthroughs into clinical success
Apr 3, 2026
CTB Blog
Even when capital flows freely, biotechs benefit from efficiency
Mar 24, 2026
CTB Blog
5 ways to secure biotech funding in 2026
Mar 19, 2026
Article
Case study: Protecting Phase 2 obesity retention and study timelines
Mar 18, 2026
CTB Webinar
Extend your funding runway: How to maintain capital efficiency in an improving market
Mar 10, 2026
Blog
Bolster your investor narrative with RWE
Jan 26, 2026
Blog
Investor-ready evidence planning: Why a robust strategy matters to funders
Dec 8, 2025